Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price Target
Benzinga Newsdesk 3 months ago
NewsUpgradesAnalyst RatingsPrice Target
Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy and announces $11 price target.
Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy and announces $11 price target.